No data to show
XTAE
EPIT
Market cap72mUSD
May 22, Last price
873.30ILS
1D
0.66%
1Q
-14.21%
IPO
-78.21%
Name
Epitomee Medical Ltd
Chart & Performance
P/E
—
P/S
725.10
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
10m
Net income
-6m
L-63.08%
CFO
-8m
L+4.68%
Profile
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. Its capsule is used for weight management, waist circumference reduction, and cardiovascular risk factors reduction. Epitomee Medical Ltd has a strategic partnership with Nestlé Health Science S.A. for the development and commercialization of the weight loss capsule. The company was incorporated in 2005 and is based in Caesarea, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 10,000 | ||||||
Cost of revenue | 7,575 | 8,586 | |||||
Unusual Expense (Income) | |||||||
NOPBT | 2,425 | (8,586) | |||||
NOPBT Margin | 24.25% | ||||||
Operating Taxes | (4,313) | ||||||
Tax Rate | |||||||
NOPAT | 2,425 | (4,273) | |||||
Net income | (5,682) -63.08% | (15,391) 33.63% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 11 | 43 | |||||
BB yield | -0.04% | ||||||
| Debt | |||||||
Debt current | 584 | 449 | 488 | ||||
Long-term debt | 8,108 | 7,467 | 7,680 | ||||
Deferred revenue | 10,000 | ||||||
Other long-term liabilities | 10,000 | ||||||
Net debt | (13,387) | (26,872) | (37,961) | ||||
| Cash flow | |||||||
Cash from operating activities | (8,293) | (7,922) | (9,421) | ||||
CAPEX | (4,615) | (4,074) | (3,698) | ||||
Cash from investing activities | 10,183 | (12,224) | (13,120) | ||||
Cash from financing activities | (509) | (454) | (328) | ||||
FCF | (12,498) | 5,910 | (11,561) | ||||
| Balance | |||||||
Cash | 22,079 | 34,788 | 46,129 | ||||
Long term investments | |||||||
Excess cash | 22,079 | 34,288 | 46,129 | ||||
Stockholders' equity | (60,204) | (58,365) | 36,474 | ||||
Invested Capital | 98,502 | 97,123 | 27,055 | ||||
ROIC | 3.91% | ||||||
ROCE | 6.26% | ||||||
| EV | |||||||
Common stock shares outstanding | 29,596 | 29,458 | |||||
Price | 9.31 150.73% | 3.71 -67.89% | 11.56 -63.42% | ||||
Market cap | 109,860 -67.74% | 340,530 512.85% | |||||
EV | 82,988 | 302,569 | |||||
EBITDA | 451 | 3,064 | (8,230) | ||||
EV/EBITDA | 27.08 | ||||||
Interest | 57 | 11 | |||||
Interest/NOPBT | 2.35% | ||||||